In our earlier research, we demonstrated that hypoxia-induced inhibition of PPARγ alleviates PAH (Wang et al., 2015), as well as the therapeutic action of PPARγ on PAH, by controlling the downstream TRPC1/6, SOCE, and hypoxia-induced PASMC proliferation (Gong et al., 2011; Zhang D. et al., 2014; Wang et al., 2015). This evidence concerns the gene PPARG and pulmonary arterial hypertension.